1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Disease Analysis: Human Papillomavirus (HPV) Vaccines

Disease Analysis: Human Papillomavirus (HPV) Vaccines

  • May 2020
  • 31 pages
  • ID: 5843159
  • Format: PDF
  • Pharma Intelligence

Summary

Table of Contents

Latest key takeaways

Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade. There are currently three approved vaccines for HPV: Cervarix, Gardasil, and Gardasil 9. Merck and Co’s Gardasil, a quadrivalent vaccine, was first-to-market with its debut in 2006, narrowly ahead of the 2007 release of GlaxoSmithKline’s rival bivalent vaccine, Cervarix. Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs). In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.
Since the launch of the first HPV vaccine in 2006, the market has seen steady growth, with global sales rising from $235m in 2006 to $2.3bn in 2016. This growth was attributed to the launch of vaccination programs in most major markets, centered on the treatment of girls aged 9–14 years and catch-up vaccinations for females aged 15–26 years. In the last two years, the HPV market has experienced unprecedented growth, and it looks set to continue this upwards trajectory. Key growth drivers include the expansion of vaccination programs to include males aged 9–26 years in major markets such as the US, UK, and Germany, rising pressure to increase coverage rates for HPV vaccination globally, and the introduction of national programs in new markets such as China. Indeed, Merck and Co attributed its $850m sales boost in 2018 to a successful launch in the Chinese market. The introduction of additional national HPV vaccination programs is projected to sustain considerable growth in the HPV market, so much so that Merck and Co has invested $1.68bn into two manufacturing plants to meet global demand for the HPV vaccine.
There remain significant factors that will limit growth of the HPV market over the next five years. One such factor is that vaccine manufacture is currently lagging behind global demand. To combat this, Merck and Co recently announced plans to establish two new manufacturing plants that should be completed by 2023.
The Gardasil franchise has always held market-leader status because of its wider serotype coverage and preferential reimbursement from payers, and with little competition from Cervarix or any major threats from pipeline candidates, it will maintain its lead for the foreseeable future.
Cervarix was the second-to-market vaccine and has experienced a sharp decline in sales from a peak of $800m in 2011, triggered by direct competition with Gardasil over market share. The global sales gap between the Gardasil franchise and Cervarix has continued to widen from $398m in 2011 to $2,964m in 2018, driven largely by preference for Gardasil 9 in major and emerging markets, and this trend is expected to continue as Gardasil 9 continues to gain uptake in the lucrative Chinese market. Sales of Cervarix have now stabilized at approximately $180m, and while the vaccine will continue to lose share in major markets, the rise of emerging markets presents opportunities for Cervarix to achieve sales growth in the near future. In particular, a shortage of supply of Gardasil 9 in emerging markets has presented GlaxoSmithKline with a small window of opportunity to drive use of Cervarix until Merck and Co can increase its supply of Gardasil 9 to meet growing demand.
Currently, there is only a single clinical pipeline candidate (in Phase I) in the HPV market, being developed by 2A Pharma outside of the US. This vaccine is based on the L2 protein, which is more conserved across different strains of HPV; the company aims to utilize this feature to generate a pan-protective vaccine. It is highly unlikely that this vaccine will gain approval during the five-year forecast period.
At the start of 2020, China’s regulator approved Cecolin, a generic HPV bivalent vaccine produced by the Chinese firm Innovax. The generic vaccine is set to be the first of a series of vaccines developed by the company, including generics for the quadrivalent and nonavalent HPV vaccines. The analyst’s discussions with KOLs indicated that there are several companies generating HPV vaccines in China and India, but their approvals in the US and EU are unlikely. There are no pipeline candidates in the US for HPV, however, there is a single pipeline candidate being developed in Europe by 2A Pharma. 2A Pharma is developing an L2 vaccine which it hypothesizes will be pan-protective based on the higher conservation of the L2 capsid protein between HPV strains. The company claims the vaccine will have broader coverage, will not require adjuvants, and will have a low production cost.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on